FOB Price
Obtenir le dernier prix0.9 ~ 1.2 / Piece ( Negotiable )
|Minimum Order
Localité:
-
Prix de commande minimale:
Commande minimale:
1000 Piece
Packaging Detail:
25 tests/box
Delivery Time:
within 7 working days
Supplying Ability:
5000000 Piece per Month
Payment Type:
T/T
Personne àcontacter Mr. David
Jianshe Road, Wuhan, Hubei
Intended Use
One Step Test for SARS-CoV*2 Antigen (Colloidal Gold) is intended for the qualitative detection of nucleocapsid protein antigen from SARS-in serum, plasma or whole blood samples from patients suspected of COVID**9 infection by a healthcare provider.
About SARS-CoV*2
The novel coronaviruses belong to the β genus. SARS-CoV*2 is an acute respiratory infectious disease. People are generally susceptible. Currently, the patients infected by the novel coronavirus are the main source of infection; asymptomatic infected people can also be an infectious source. Based on the current epidemiological investigation, the incubation period is 1 to *4 days, mostly 3 to 7 days. The main manifestations include fever, fatigue and dry cough. Nasal congestion, runny nose, sore throat, myalgia and diarrhea are found in a few cases.
Contents
A kit contains:
Package specifications: *5 tests/box
1) Getein SARS-CoV*2 antigen test card in a sealed pouch with desiccant
2) Sample extraction solution: *5 tubes/box
3) Sampling swab: *5 pieces/box
4) Disposable pipette: *5 pieces/box
5) User manual: 1 piece/box
Note: Do not mix or interchange different batches of kits.
| Test Item | Sample | Storage Condition |
| SARS-CoV*2 Antigen | Human nasal swab | ***0℃ |
| Method | Test Time | Shelf Life |
| Colloidal Gold | ****5 min | *4 months |
Clinical Application
1. This test is an aid in the diagnosis of patients with suspected SARS-CoV*2 infection in conjunction with clinical presentation and the results of other laboratory tests.
2. This test is only intended for professional and laboratory use, not for home testing.
3. Results from the test should not be used as the sole basis for diagnosis and exclusion of SARS-CoV*2 infection.
4. As it is a novel disease diagnosis of which are being explored, please refer to the latest guidelines for diagnosis and treatment of COVID**9.
